Endoglin promoter hypermethylation identifies a field defect in human primary esophageal cancer

Endoglin (ENG) is a 180‐kilodalton transmembrane glycoprotein that functions as a component of the transforming growth factor‐β receptor complex. Recently, ENG promoter hypermethylation was reported in several human cancers.

[1]  J. Reis-Filho,et al.  Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome , 2011, Oncogene.

[2]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[3]  M. Guo,et al.  The value of epigenetic markers in esophageal cancer , 2010, Frontiers of medicine in China.

[4]  Li Dong Wang,et al.  Identification of an invasion and tumor‐suppressing gene, Endoglin (ENG), silenced by both epigenetic inactivation and allelic loss in esophageal squamous cell carcinoma , 2008, International journal of cancer.

[5]  C. Roehrborn,et al.  Improved Prediction of Disease Relapse after Radical Prostatectomy through a Panel of Preoperative Blood-Based Biomarkers , 2008, Clinical Cancer Research.

[6]  D. Beer,et al.  Hypermethylation of the AKAP12 Promoter is a Biomarker of Barrett's-Associated Esophageal Neoplastic Progression , 2008, Cancer Epidemiology Biomarkers & Prevention.

[7]  D. Beer,et al.  Hypermethylation of Tachykinin-1 Is a Potential Biomarker in Human Esophageal Cancer , 2007, Clinical Cancer Research.

[8]  Tetsuo Ito,et al.  Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma , 2007, Oncogene.

[9]  N. Matsubara,et al.  Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa , 2006, Gut.

[10]  G. Nuovo,et al.  Hypermethylation of the MLH1 Promoter With Concomitant Absence of Transcript and Protein Occurs in Small Patches of Crypt Cells in Unaffected Mucosa From Sporadic Colorectal Carcinoma , 2006, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[11]  R. Momparler.  Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine). , 2005, Seminars in oncology.

[12]  M. Pepe,et al.  Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk , 2005, Oncogene.

[13]  S. Burdach,et al.  CpG island methylation and expression of tumour-associated genes in lung carcinoma. , 2005, European journal of cancer.

[14]  M. Bernstein,et al.  Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia , 2005, Anti-cancer drugs.

[15]  S. Kyo,et al.  Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers , 2003, Oncogene.

[16]  Manel Esteller,et al.  Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. , 2003, Cancer research.

[17]  P. Stattin,et al.  Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer , 2002, The Prostate.

[18]  M. Maio,et al.  Endoglin: An accessory component of the TGF‐β‐binding receptor‐complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies , 2001, Journal of cellular physiology.

[19]  Jun Yu,et al.  Concurrent hypermethylation of multiple tumor‐related genes in gastric carcinoma and adjacent normal tissues , 2001, Cancer.

[20]  A. Ramaswamy,et al.  Elevated expression of endoglin, a component of the TGF‐β‐receptor complex, correlates with proliferation of tumor endothelial cells , 1999, International journal of cancer.

[21]  Shant Kumar,et al.  Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. , 1999, Cancer research.

[22]  J. Hughes,et al.  Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. , 1997, American journal of human genetics.

[23]  A. Gazdar,et al.  Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  A. Guttmacher,et al.  Six novel mutations in the endoglin gene in hereditary hemorrhagic telangiectasia type 1 suggest a dominant-negative effect of receptor function. , 1995, Human molecular genetics.

[25]  J. Massagué,et al.  Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. , 1992, The Journal of biological chemistry.

[26]  M. Letarte,et al.  Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. , 1990, The Journal of biological chemistry.

[27]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[28]  GASTROENTEROLOGY 2006;131:797–808 BASIC–ALIMENTARY TRACT A Genome-Wide Search Identifies Epigenetic Silencing of Somatostatin, , 2022 .